ARCELLX INC (NASDAQ: ACLX)

ARCELLX INC

NASDAQ: ACLX (Arcellx, Inc.)

Last update: 2 days ago, 11:47PM

114.77

0.44 (0.38%)

Add to watchlist

Previous Close	114.33
Open	114.60
Volume	3,173,199
Avg. Volume (3M)	2,177,730
Market Cap	6,711,727,616

Price / Sales	289.97
Price / Book	16.68

52 Weeks Range	47.86 (-58%) — 114.91 (0%)
Earnings Date	7 May 2026

Market Trend

		Short Term	Medium Term
Industry	Biotechnology (US)	Bullish	Mixed
	Biotechnology (Global)	Bullish	Mixed
Stock	Arcellx, Inc.	Bullish	Bullish

AIStockmoo Score

-0.6

Analyst Consensus	1.5
Insider Activity	-3.0
Price Volatility	-3.0
Technical Moving Averages	-2.5
Technical Oscillators	4.0
Average	-0.60

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
ACLX	7 B	-	-	16.68
PCVX	8 B	-	-	2.93
TERN	5 B	-	-	18.30
VKTX	4 B	-	-	6.42
CRNX	4 B	-	-	3.75
EWTX	3 B	-	-	6.12

Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Sector	Healthcare
Industry	Biotechnology
Investment Style	Small Core
% Held by Insiders	14.50%
% Held by Institutions	102.08%

Ownership

Name	Date	Shares Held
Gilead Sciences, Inc.	31 Dec 2025	6,720,803

52 Weeks Range	47.86 (-58%) — 114.91 (0%)
Price Target Range	105.00 (-8%) — 120.00 (4%)
High	120.00 (Truist Securities, 4.56%)	Hold
Median	115.00 (0.20%)
Low	105.00 (Needham, -8.51%)	Buy
Average	114.55 (-0.19%)
Total	1 Buy, 10 Hold
Avg. Price @ Call	109.51

Firm	Date	Target Price	Call	Price @ Call
Guggenheim	26 Feb 2026	115.00 (0.20%)	Hold	113.88
Citigroup	24 Feb 2026	115.00 (0.20%)	Hold	113.75
Evercore ISI Group	24 Feb 2026	115.00 (0.20%)	Hold	113.75
Leerink Partners	24 Feb 2026	115.00 (0.20%)	Hold	113.75
Stifel	24 Feb 2026	115.00 (0.20%)	Hold	113.75
Truist Securities	24 Feb 2026	120.00 (4.56%)	Hold	113.75
UBS	24 Feb 2026	115.00 (0.20%)	Hold	113.75
UBS	07 Jan 2026	100.00 (-12.87%)	Buy	65.01
Baird	23 Feb 2026	115.00 (0.20%)	Hold	113.75
HC Wainwright & Co.	23 Feb 2026	115.00 (0.20%)	Hold	113.75
HC Wainwright & Co.	04 Feb 2026	115.00 (0.20%)	Buy	69.38
Wells Fargo	23 Feb 2026	115.00 (0.20%)	Hold	113.75
Needham	05 Feb 2026	105.00 (-8.51%)	Buy	66.94
Show more

Name	Avg. Buy ($)	Avg. Sell ($)	Net Quantity	Net Value ($)
GILSON MICHELLE	-	114.52	-5,000	-572,600
Aggregate Net Quantity				-5,000
Aggregate Net Value ($)				-572,600
Aggregate Avg. Buy ($)				-
Aggregate Avg. Sell ($)				114.52

Name	Holder	Date	Type	Quantity	Price	Value ($)
GILSON MICHELLE	Officer	17 Mar 2026	Disposed (-)	5,000	114.52	572,600

Date	Type	Details
04 Feb 2026	Announcement	Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel’s D-Domain Binder
21 Jan 2026	Announcement	Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2026	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Profit Margin	-211.46%
Operating Margin (TTM)	-847.56%
Diluted EPS (TTM)	-2.99
Quarterly Revenue Growth (YOY)	-79.30%

Total Debt/Equity (MRQ)	12.76%
Current Ratio (MRQ)	4.93
Operating Cash Flow (TTM)	-114.70 M
Levered Free Cash Flow (TTM)	-10.43 M

Return on Assets (TTM)	-16.69%
Return on Equity (TTM)	-35.56%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)